- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 04.12. | Tracey Beth Høeg, top Makary deputy, named head of FDA drug office | ||
| 04.12. | UniQure slides further on outlook for Huntington's gene therapy | ||
| 03.12. | After finding 'irregularities,' Bristol Myers to extend key trial of Cobenfy in Alzheimer's psychosis | ||
| 03.12. | Capricor soars on positive results for Duchenne cell therapy | ||
| 03.12. | Pharvaris' pill succeeds in late-stage trial for rare swelling disorder | ||
| 02.12. | Richard Pazdur, FDA drug czar, to retire from agency | ||
| 02.12. | FDA details plan to scale back animal tests for some antibody drugs | ||
| 02.12. | Janux sinks on 'overreaction' to prostate cancer data; RFK Jr. replaces ACIP chair | ||
| 02.12. | The 'clever' tool increasingly getting bigger biotech deals signed | ||
| 01.12. | UK agrees to boost drug prices to dodge US pharma tariffs | ||
| 01.12. | Regeneron inks gene editing deal with startup Tessera | ||
| 01.12. | Belite continues ascent as Stargardt drug hits mark in late-stage trial | ||
| 01.12. | With $130M, Protego pushes forward a new type of amyloidosis drug | ||
| 01.12. | From feedstocks to infrastructure, Indiana's bioeconomy is on the move | ||
| 01.12. | Specialty pharmacy's secret weapon: The unsung power of the enrollment form | ||
| 01.12. | Expanding access in oncology trials: The case for a paired tissue-plasma approach | ||
| 26.11. | Otsuka gains approval for first-of-its-kind treatment against rare kidney disease | ||
| 26.11. | Novartis cuts hundreds of jobs; Novo's dual-acting diabetes drug heading to Phase 3 | ||
| 26.11. | CMS sets 2027 Medicare prices for Wegovy, Trelegy and 13 other drugs | ||
| 25.11. | Novartis wins approval to use SMA gene therapy in older patients | ||
| 25.11. | Gilead scoops up a preclinical cancer program | ||
| 25.11. | How do Big Pharma employees rate their CEOs? | ||
| 24.11. | Bayer's experimental blood-thinner notches trial win in stroke prevention | ||
| 24.11. | Novo Nordisk's GLP-1 misses goal in closely watched Alzheimer's studies | ||
| 24.11. | FDA probes effects of Takeda rare disease drug after patient death |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .